Ocugen Investoren 2022 WKN: A2PSZH ISIN: US67577C1053 Forum: Aktien User: Ad_Astra

Wat rennen eigentlich diese ganzen Flachpfeifen noch hier umher . Dieser Jens auf wieder 😂

https://x.com/ocugen/status/1716444005632778489?s=46&t=EXaC4wXwS71BbmJHwvwGrQ

😂😂😂😂😂😂👍🏻

Sei’s drum . Wichtig ist für mich was die nächsten Tage passiert mit dem kurs.

Von ocugen Presse Abteilung wissen wir ja , wie schleppend alles läuft. Auf jedem Fall gibt es Seiten OC kein Statement bisher. Meine die Dame hatte schon einen sehr wichtigen Aufgabe bei OC.

https://finance.yahoo.com/news/medicus-pharma-ltd-announces-closing-203600374.html

https://stockhouse.com/news/newswire/2023/10/11/medicus-pharma-a-holding-company-to-supercharge-your-healthcare-allocation

Das ist der neue Arbeitgeber

Sie ist noch auf der Website von OC. Vielleicht wird Homepage noch überarbeitet.

Medicus Pharma Ltd. Announces Appointment of Huma Qamar, MD as Chief Scientific Officer & Head of R&D Program Elects James P. Quinlan as Chairman of Skinject Inc. Toronto, Ontario--(Newsfile Corp. - October 18, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Huma Qamar, MD as the Chief Scientific Officer & Head of R&D Program. Dr. Qamar has worked in the clinical research field for some of the most renowned Ivy league institutions such as Yale University, Harvard University and the University of Pennsylvania. She has robust experience in developing Phase I-IV clinical protocols and execution of clinical studies, FDA inspections, billing and compliance audits, and medical affairs team management. She has expertise in multiple therapeutic areas, including Oncology (Heme-Onc, CAR-T, rare tumors, sarcoma, melanoma, Women's health, GU & GI, fetal oncology), gene therapy, vaccines, rheumatology, dermatology, neurology, cardiology, hepatology, and infectious diseases. Dr. Qamar was most recently serving as the Head of Clinical Development & Clinical Operations at Ocugen Inc.